Efficacy and safety of donepezil in patients with Alzheimer's disease - Results of a. global, multinational, clinical experience study

Boada-Rovira M., Brodaty H., Cras P., Baloyannis S., Emre M., Zhang R., ...Daha Fazla

DRUGS & AGING, cilt.21, sa.1, ss.43-53, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 1
  • Basım Tarihi: 2004
  • Doi Numarası: 10.2165/00002512-200421010-00004
  • Dergi Adı: DRUGS & AGING
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.43-53
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Background: Donepezil has consistently been shown to be effective and well tolerated in the symptomatic treatment of Alzheimer's disease in placebo-controlled clinical trials. It has been shown to provide significant benefits in cognition, global function and activities of daily living in patients with mild-to-moderate Alzheimer's disease. However, in order to control for confounding factors, some clinical trials of donepezil have excluded patients with comorbid illness and concomitant medication use.